EDI-200

Summary

EDI-200 (also known as APO200 or ER004) is an investigational agonist monoclonal antibody targeting EDAR, developed primarily for the treatment of X-linked hypohidrotic ectodermal dysplasia (XLHED), a rare genetic disorder caused by loss-of-function mutations in the EDA gene. Early intervention during fetal or neonatal life is critical as ectodermal structures must develop during a narrow developmental window. Clinical trials have evaluated prenatal and postnatal administration. It has received Orphan Drug and Breakthrough Therapy designations.

Mechanism of Action

EDI-200 is a fully human agonist monoclonal antibody that binds to and activates EDAR (ectodysplasin A receptor), mimicking the function of EDA-A1 (ectodysplasin-A isoform 1). This activation of the EDA/EDAR/NF-κB signaling pathway promotes the development of ectodermal appendages including sweat glands, teeth, and hair follicles during fetal and neonatal development.

Routes of Administration

Goals & Uses

• Treatment of XLHEDRare Genetic DiseaseModerate
• Restoration of sweat gland developmentRare Disease / Ectodermal DysplasiaModerate
• Improvement of dental and hair developmentRare Disease / Ectodermal DysplasiaLow
• Prevention of hyperthermia riskSymptom PreventionModerate

Contraindications

• Known hypersensitivity to EDI-200 or its componentsAllergy / ImmunologyHigh
• Infections not under adequate treatmentInfectious DiseaseModerate

Adverse Effects

• Transient laboratory abnormalitiesLaboratoryUncommon
• FeverSystemicUncommonElevated body temperature
• Potential immunogenicity (ADA formation)ImmunologicUnknown
• Infusion-related reactionsHypersensitivityUncommon

Drug Interactions

• ImmunosuppressantsModeratePotential interaction with immune pathways or infection risk

Population Constraints

• Pregnant women (fetal administration)PregnancyRelative
• Patients with active infectionsInfectious DiseaseRelative
• Pediatric neonatesAgeRelative

Regulatory Status

• European UnionInvestigationalOrphan Drug Designation granted by EMA for XLHED; not yet approved
• United StatesInvestigationalOrphan Drug Designation and Breakthrough Therapy Designation granted by FDA; not yet approved

Granted Orphan Drug Designation by the FDA and EMA for XLHED. Received Breakthrough Therapy Designation from the FDA. Not yet approved for marketing. Developed by Edimer Pharmaceuticals and later associated with Syndax/other sponsors.

Evidence & Sources

No sources recorded yet.